Loading...
More about masitinib
A dose-escalating phase II trial studied masitinib, an oral tyrosine kinase inhibitor, in 43 patients with rheumatoid arthritis. Masitinib induced American College of Rheumatology (ACR)20, ACR50 and ACR70 responses in 54%, 26% and 8% of patients, respectively. A placebo group was not included. Thirt...
Na minha lista:
| Hovedforfatter: | |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2009
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2745773/ https://ncbi.nlm.nih.gov/pubmed/19664170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar2734 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|